**Study Overview:** This research is about finding out how safe and effective a medicine called *paricalcitol* is for treating kids aged 0 to 9 with a condition called secondary hyperparathyroidism (SHPT), which is linked to severe kidney problems (stage 5 chronic kidney disease, or CKD). These kids receive special treatments called peritoneal dialysis (PD) or hemodialysis (HD) to help their kidneys. The study lasts for 24 weeks, broken into two parts, each lasting 12 weeks.
**Key Points:**
- **Commitment:** Participants will be involved for 24 weeks, with two 12-week dosing periods.
- **Eligibility:** Must have SHPT, be on PD or HD for at least 30 days, and meet lab criteria.
- **Restrictions:** No recent kidney transplant, certain medication use, or surgeries are allowed.
This study is important because it could help children with severe kidney issues. However, joining requires several visits and strict eligibility criteria.
How understandable was the trial content above?
Hard to understand
Easy to understand